SCYNEXIS, Inc.
SCYNEXIS, Inc. (Nasdaq: SCYX) is a biotechnology company developing treatments for severe rare diseases, with a focus on difficult-to-treat and drug-resistant fungal infections. Its proprietary “fungerp” platform comprises triterpenoid antifungal agents that inhibit glucan synthase and have activity against a range of… From the company’s description.
Over the twelve months to Sep 30, 2026, SCYNEXIS, Inc. reported revenue of $18.88M, up 544.0% from a year earlier, and a net loss of $10.10M. Its operating margin was −126.9%, and operations used $12.05M in cash. In fiscal 2025, it reported revenue of $20.60M, up 449.9% from fiscal 2024, and a net loss of $8.61M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What SCYNEXIS, Inc. does
In the company’s own words
SCYNEXIS, Inc. (Nasdaq: SCYX) is a biotechnology company developing treatments for severe rare diseases, with a focus on difficult-to-treat and drug-resistant fungal infections. Its proprietary “fungerp” platform comprises triterpenoid antifungal agents that inhibit glucan synthase and have activity against a range of fungal pathogens. The company’s lead development candidate, SCY-247, is being studied in oral and intravenous formulations for invasive candidiasis and prevention of invasive fungal infections in high-risk patients. Its first-generation fungerp, ibrexafungerp, is approved in the United States as BREXAFEMME for vulvovaginal candidiasis and prevention of recurrent vulvovaginal candidiasis; SCYNEXIS licensed its development and commercialization to GSK in 2023. Hansoh holds rights to ibrexafungerp in Greater China, while R-Pharm holds rights in Russia and certain other countries. SCYNEXIS also licenses other development assets to partners, including SCY-635 for viral diseases. The company’s business centers on research and development and partner licensing rather than multiple reportable operating segments.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- JERSEY CITY, NJ
- Fiscal year end
- December
- CIK
- 1178253
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns SCYNEXIS, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · SCYNEXIS, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do SCYNEXIS, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of SCYNEXIS, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in SCYNEXIS, Inc.'s last four quarterly filings that the numbers alone won't show?”